59237-53-5

Basic information

• Product Name: Methyl-6-chloro-5-nitronicotinate
• Synonyms: Methyl-6-chloro-5-nitronicotite;Methyl-6-chloro-5-nitronicotinate;6-Chloro-5-nitro-3-pyridinecarboxylic acid;6-Chloro-5-nitropyridine-3-carboxylic acid methyl ester;methyl 6-chloro-5-nitronicotinate(SALTDATA: FREE);Methyl 6-chloro-5-nitropyridine-3-carboxylate, 2-Chloro-5-(methoxycarbonyl)-3-nitropyridine;6-chloro-5-nitropyridine-3-carboxylic acid;3-Pyridinecarboxylic acid, 6-chloro-5-nitro-, Methyl ester
• CAS NO: 59237-53-5
• Molecular Formula: C₇H₅ClN₂O₄
• Molecular Weight: 216.5786
• Mol File: 59237-53-5.mol
• Article Data: 17

Chemical Properties

• Melting Point: 76 °C
• Boiling Point: 317.8 °C at 760 mmHg
• Flash Point: 146 °C
• Appearance: /
• Density: 1.5 g/cm³
• Vapor Pressure: 0.000375mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.81±0.10(Predicted)
• CAS DataBase Reference: Methyl-6-chloro-5-nitronicotinate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl-6-chloro-5-nitronicotinate(59237-53-5)
• EPA Substance Registry System: Methyl-6-chloro-5-nitronicotinate(59237-53-5)

Safety Data

• Hazardous Substances Data: 59237-53-5(Hazardous Substances Data)

Usage

Uses

6-Chloro-5-nitronicotinic Acid Methyl Ester, is a building block used for the synthesis of various pharmaceutical compounds, such as anticoccidial agents.

InChI:InChI=1/C7H5ClN2O4/c1-14-7(11)4-2-5(10(12)13)6(8)9-3-4/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 7477-10-3 6-chloro-5-nitronicotinic acid 
• 6635-31-0 6-hydroxy-5-nitronicotinic acid 
• 74-88-4 methyl iodide 
• 5006-66-6 6-hydroxy-3-pyridinecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 23945-84-8 6-chloro-5-nitro-nicotinoyl chloride 

Downstream Products

• 1236119-50-8 Methyl 6-(benzyl(2-ethoxy-2-oxoethyl)amino)-5-nitronicotinate 
• 30766-27-9 methyl 5-nitronicotinate 
• 104685-76-9 5,6-diamino-nicotinic acid methyl ester 
• 211915-52-5 methyl 6-(methylamino)-5-nitronicotinate 

Relevant articles and documents

3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity

Several retinoid X receptor (RXR) ligands (rexinoids), such as bexarotene (1), exhibit teratogenicity, which is a serious impediment to their clinical application. We considered that rexinoids with a lower level of maximal RXR transcription activation (i.e., partial agonists) and lower lipid solubility might show weaker adverse side effects. Based on this idea, we modified our previously reported pentamethyltetralin-type RXR partial agonists 5 and 6 to reduce their lipophilicity. Here, we report a new RXR partial agonist, 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine-6-carboxylic acid (8, CATF-PMN), which showed greatly reduced teratogenicity in zebrafish embryos.

Development of BET inhibitors as potential treatments for cancer: A new carboline chemotype

We describe our efforts to introduce structural diversity to a previously described triazole-containing N1-carboline series of bromodomain and extra-terminal (BET) inhibitors. N9 carbolines were designed to retain favorable binding interactions that the N1-carbolines possess. A convergent synthetic route enabled modifications to reduce clearance, enhance physicochemical properties, and improve the overall in vitro profile. This work led to the identification of a potent BET inhibitor, (S)-2‐{8‐fluoro‐5‐[(3‐fluoropyridin‐2‐yl)(oxan‐4‐yl)methyl]‐7‐[4‐(2H3)methyl‐1‐methyl‐1H‐1,2,3‐triazol‐5‐yl]‐5H‐pyrido[3,2‐b]indol‐3‐yl}propan‐2‐ol (10), a compound with enhanced oral exposure in mice. Subsequent evaluation in a mouse triple-negative breast cancer tumor model revealed efficacy at 4 mg/kg of N9-carboline 10.

TRICYCLIC COMPOUNDS AS ANTICANCER AGENTS

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.